OncData's profile picture. #OncData delivers up-to-date, clinically relevant content for the multidisciplinary #cancer care team including the latest medical news, research, and more.

Oncology Data Advisor

@OncData

#OncData delivers up-to-date, clinically relevant content for the multidisciplinary #cancer care team including the latest medical news, research, and more.

The #FDA granted accelerated approval to the oral kinase inhibitor #sevabertinib for locally advanced or metastatic, non-squamous non–small cell #LungCancer (#NSCLC). 🔗Learn more about the #approval and the #SOHO01 trial here: oncdata.com/sevabertinib-g… #Oncology

OncData's tweet image. The #FDA granted accelerated approval to the oral kinase inhibitor #sevabertinib for locally advanced or metastatic, non-squamous non–small cell #LungCancer (#NSCLC).

🔗Learn more about the #approval and the #SOHO01 trial here: oncdata.com/sevabertinib-g…

#Oncology

At #ESMO25, new data reinforced evolving standards in #prostate cancer. After returning from the meeting, @SFreedlandMD (@CedarsSinai) and Dr. Murilo Luz (@MountSinaiNYC) sat down to interpret some of the most influential data. Watch here! youtu.be/N9bk2GHXL6M @myESMO

OncData's tweet image. At #ESMO25, new data reinforced evolving standards in #prostate cancer. After returning from the meeting, @SFreedlandMD (@CedarsSinai) and Dr. Murilo Luz (@MountSinaiNYC) sat down to interpret some of the most influential data.

Watch here! youtu.be/N9bk2GHXL6M

@myESMO

At #ESMO25, @SFreedlandMD presented new survival results of the #EMBARK trial of #enzalutamide in high-risk biochemically recurrent #prostate cancer. Here, he shares how to apply these data in practice and tips for patient selection. Watch here! youtu.be/TR4hXNWgivU #PCsm

OncData's tweet image. At #ESMO25, @SFreedlandMD presented new survival results of the #EMBARK trial of #enzalutamide in high-risk biochemically recurrent #prostate cancer. Here, he shares how to apply these data in practice and tips for patient selection.

Watch here! youtu.be/TR4hXNWgivU

#PCsm

The #FDA approved #epcoritamab-bysp in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma. 🔗Learn more about the #EPCOREFL1 trial and the #approval here: oncdata.com/epcoritamab-by…

OncData's tweet image. The #FDA approved #epcoritamab-bysp in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma.

🔗Learn more about the #EPCOREFL1 trial and the #approval here: oncdata.com/epcoritamab-by…

The #FDA approved #ziftomenib for relapsed or refractory acute myeloid #leukemia (#AML) with a susceptible (#NPM1) mutation. 🔗Learn more about the #KOMEN001 trial and the #approval here: oncdata.com/ziftomenib-app…

OncData's tweet image. The #FDA approved #ziftomenib for relapsed or refractory acute myeloid #leukemia (#AML) with a susceptible (#NPM1) mutation. 

🔗Learn more about the #KOMEN001 trial and the #approval here: oncdata.com/ziftomenib-app…

Dr. Christopher Iannuzzi, Medical Director of #Radiation Oncology and Chair of Oncology at @StVincentsMC, @HartfordHealthC, shares how #adaptive #intelligence is personalizing #prostate cancer radiation and refining treatment precision. Watch here! youtu.be/1P5xS4sU0sg?si… #PCsm

OncData's tweet image. Dr. Christopher Iannuzzi, Medical Director of #Radiation Oncology and Chair of Oncology at @StVincentsMC, @HartfordHealthC, shares how #adaptive #intelligence is personalizing #prostate cancer radiation and refining treatment precision.

Watch here! youtu.be/1P5xS4sU0sg?si…

#PCsm

Oncology Data Advisor is proud to announce Matthew Hadfield, DO, as Editor in Chief! Read the announcement here: bit.ly/4i1uCxV And watch an exclusive interview with Dr. Hadfield and outgoing Editor in Chief, @RahulBanerjeeMD, here! youtube.com/watch?v=pB5zr1…

OncData's tweet image. Oncology Data Advisor is proud to announce Matthew Hadfield, DO, as Editor in Chief! 

Read the announcement here: bit.ly/4i1uCxV

And watch an exclusive interview with Dr. Hadfield and outgoing Editor in Chief, @RahulBanerjeeMD, here! youtube.com/watch?v=pB5zr1…

Oncology Data Advisor reposted

#Repost of this insightful and compassionate conversation about caregiving that I had last year that is still relevant today. Thank you @OncData for amplifying our voices. youtu.be/EGYOGFngIJg?si… #CaregiversAwarenessMonth #OncologyDataAdvisor #Caregiver

warriormegsie's tweet card. National Family Caregivers Month: Stories and Support for Caregivers

youtube.com

YouTube

National Family Caregivers Month: Stories and Support for Caregivers


Watch as @WaqasHaqueMD speaks with @MaryPasquinelli, DNP (@thisisUIC) about the evolving role of #AI in #LungCancer detection—including #Sybil, a deep learning model with benefits for predicting future lung cancer risk in a diverse population. Watch here! youtu.be/UjK0gjx1gFc?si…

OncData's tweet image. Watch as @WaqasHaqueMD speaks with @MaryPasquinelli, DNP (@thisisUIC) about the evolving role of #AI in #LungCancer detection—including #Sybil, a deep learning model with benefits for predicting future lung cancer risk in a diverse population.

Watch here! youtu.be/UjK0gjx1gFc?si…

Radiation oncologist Dr. Sean Collins (@SbrtSean) of @TGHCares sat down to discuss new real-world evidence on hydrogel rectal #spacers in #ProstateCancer radiotherapy, including new insights from his team's analysis presented at #ASTRO25. Watch here! youtu.be/KeRbtQHO4Ts?si…

OncData's tweet image. Radiation oncologist Dr. Sean Collins (@SbrtSean) of @TGHCares sat down to discuss new real-world evidence on hydrogel rectal #spacers in #ProstateCancer radiotherapy, including new insights from his team's analysis presented at #ASTRO25.

Watch here! youtu.be/KeRbtQHO4Ts?si…

The #FDA approved #revumenib for relapsed or refractory acute myeloid leukemia (#AML) with a susceptible nucleophosmin 1 (#NPM1) mutation. 🔗Learn more about the #AUGMENT101 trial and approval here: oncdata.com/revumenib-appr…

OncData's tweet image. The #FDA approved #revumenib for relapsed or refractory acute myeloid leukemia (#AML) with a susceptible nucleophosmin 1 (#NPM1) mutation. 

🔗Learn more about the #AUGMENT101 trial and approval here: oncdata.com/revumenib-appr…

#MARS2 sparked controversy on surgery for pleural #mesothelioma. In this interview, @JVelottaMD discusses the trial's limitations, which patients may still benefit from surgery, why multidisciplinary staging remains essential, and more! 🔗Watch here: oncdata.com/mars-2-mesothe…

OncData's tweet image. #MARS2 sparked controversy on surgery for pleural #mesothelioma. In this interview, @JVelottaMD discusses the trial's limitations, which patients may still benefit from surgery, why multidisciplinary staging remains essential, and more!

🔗Watch here: oncdata.com/mars-2-mesothe…

The #FDA approved #belantamab mafodotin‑blmf in combination with bortezomib and dexamethasone (#BVd) for adults with relapsed or refractory multiple #myeloma. 🔗Learn about the #DREAMM7 trial and approval here: oncdata.com/belantamab-maf…

OncData's tweet image. The #FDA approved #belantamab mafodotin‑blmf in combination with bortezomib and dexamethasone (#BVd) for adults with relapsed or refractory multiple #myeloma.

🔗Learn about the #DREAMM7 trial and approval here: oncdata.com/belantamab-maf…

In this #BreastCancerAwarenessMonth interview, Armaan Jamal, PhD student in Epidemiology at @UChicagoPHS, discusses his team’s work investigating factors associated with fear of breast cancer recurrence, presented at #ASCOQLTY25. Watch here! youtu.be/XxDWOK0Tao8 @ASCO #BCsm

OncData's tweet image. In this #BreastCancerAwarenessMonth interview, Armaan Jamal, PhD student in Epidemiology at @UChicagoPHS, discusses his team’s work investigating factors associated with fear of breast cancer recurrence, presented at #ASCOQLTY25.

Watch here! youtu.be/XxDWOK0Tao8

@ASCO #BCsm

For International #Mastocytosis and #MastCell Diseases #Awareness Day, Dr. Mariana Castells of @BrighamWomens shares updates to her CME/NCPD activity on #SystemicMastocytosis, including advances in diagnosis, treatment, and collaboration. Watch here! youtu.be/-zt95-TOOiA

OncData's tweet image. For International #Mastocytosis and #MastCell Diseases #Awareness Day,  Dr. Mariana Castells of @BrighamWomens shares updates to her CME/NCPD activity on #SystemicMastocytosis, including advances in diagnosis, treatment, and collaboration. 

Watch here! youtu.be/-zt95-TOOiA

In this #BreastCancerAwarenessMonth interview, Kisha Cummings, @warriormegsie, and @HundalJasmin explore the journey through #breast cancer diagnosis, treatment, and #survivorship—including moving beyond awareness to actionable change. Watch here! youtu.be/XQ3kFP1Cvk8 #BCAM

OncData's tweet image. In this #BreastCancerAwarenessMonth interview, Kisha Cummings, @warriormegsie, and @HundalJasmin explore the journey through #breast cancer diagnosis, treatment, and #survivorship—including moving beyond awareness to actionable change.

Watch here! youtu.be/XQ3kFP1Cvk8

#BCAM

The #FDA has approved #cemiplimab‑rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (#CSCC) at high risk of recurrence following #surgery and #radiation. 🔗Learn more about the #CPOST and the #approval here: oncdata.com/cemiplimab-app…

OncData's tweet image. The #FDA has approved #cemiplimab‑rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (#CSCC) at high risk of recurrence following #surgery and #radiation.

🔗Learn more about the #CPOST and the #approval here: oncdata.com/cemiplimab-app…

In honor of #BreastCancerAwarenessMonth, @HundalJasmin (@ClevelandClinic) and @MatthewKurianMD (@StElizabethNKY) sat down to discuss priorities in #awareness, including nuances in #screening, male breast cancer, community, and advocacy. Watch here! youtu.be/LidVnF9CzvU #BCAM

OncData's tweet image. In honor of #BreastCancerAwarenessMonth, @HundalJasmin (@ClevelandClinic) and @MatthewKurianMD (@StElizabethNKY) sat down to discuss priorities in #awareness, including nuances in #screening, male breast cancer, community, and advocacy.

Watch here! youtu.be/LidVnF9CzvU

#BCAM

In this AI series episode, @WaqasHaqueMD speaks with @TravisOsterman of @VUMChealth about the evolving role of health #informatics in oncology, including training pathways and strategies to promote adoption in academic and community practices. Watch here! youtu.be/scdkvBZH7l4

OncData's tweet image. In this AI series episode, @WaqasHaqueMD speaks with @TravisOsterman of @VUMChealth about the evolving role of health #informatics in oncology, including training pathways and strategies to promote adoption in academic and community practices.

Watch here! youtu.be/scdkvBZH7l4

The #FDA approved #lurbinectedin plus atezolizumab or atezolizumab and hyaluronidase‑tqjs for the maintenance treatment of adults with extensive‑stage small–cell #LungCancer (#ESSCLC). 🔗Learn more about the approval and the #IMforte trial here: oncdata.com/lurbinectedin-…

OncData's tweet image. The #FDA approved #lurbinectedin plus atezolizumab or atezolizumab and hyaluronidase‑tqjs for the maintenance treatment of adults with extensive‑stage small–cell #LungCancer (#ESSCLC).

🔗Learn more about the approval and the #IMforte trial here: oncdata.com/lurbinectedin-…

Loading...

Something went wrong.


Something went wrong.